LOGIN  |  REGISTER
Cue Biopharma

List of Biotech and Pharma Companies Using Artificial Intelligence

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 821.67
-5.09 -0.62
1.96M
899.32M
US$ 738.940B
US$ 42.37
-0.26 -0.61
418,260
5.52B
US$ 233.880B
US$ 367.54
-0.23 -0.06
1.07M
381.22M
US$ 140.110B
US$ 88.98
0.75 0.85
6.70M
1.28B
US$ 113.890B
US$ 237.48
1.87 0.79
897,668
162.35M
US$ 38.550B
US$ 81.66
0.66 0.81
2.96M
456.87M
US$ 37.310B
US$ 179.36
-0.66 -0.37
1.36M
181.50M
US$ 32.550B
US$ 69.47
-2.66 -3.69
5.41M
390.60M
US$ 27.130B
US$ 95.40
-0.50 -0.52
703,835
239.74M
US$ 22.870B
US$ 112.15
1.51 1.36
1.02M
199.07M
US$ 22.330B
US$ 166.00
-0.62 -0.37
845,348
111.62M
US$ 18.530B
US$ 180.11
1.33 0.74
1.46M
82.56M
US$ 14.870B
US$ 62.32
0.84 1.37
1.25M
225.72M
US$ 14.070B
US$ 107.34
-0.02 -0.02
589,285
121.70M
US$ 13.060B
US$ 82.28
-0.55 -0.66
1.73M
158.60M
US$ 13.050B
US$ 28.41
0.00 0.00
633,179
435.99M
US$ 12.390B
US$ 32.12
0.64 2.03
6.15M
384.82M
US$ 12.360B
US$ 60.68
-0.58 -0.95
1.26M
192.65M
US$ 11.690B
US$ 59.95
0.57 0.96
1.47M
158.89M
US$ 9.530B
US$ 39.65
0.07 0.18
624,972
222.26M
US$ 8.810B
US$ 158.06
-0.19 -0.12
585,019
51.14M
US$ 8.080B
US$ 51.97
-1.28 -2.40
9.31M
152.40M
US$ 7.920B
US$ 88.83
-0.39 -0.44
1.45M
86.66M
US$ 7.700B
US$ 38.54
0.86 2.28
1.74M
172.09M
US$ 6.630B
US$ 27.49
-1.27 -4.42
1.10M
186.89M
US$ 5.140B
US$ 50.67
-0.05 -0.10
786,970
74.03M
US$ 3.750B
US$ 94.34
-2.10 -2.18
557,354
27.47M
US$ 2.590B
US$ 50.65
-0.36 -0.71
427,947
38.23M
US$ 1.940B
US$ 10.12
-0.03 -0.30
1.05M
160.99M
US$ 1.630B
US$ 3.70
-0.03 -0.80
4.60M
412.08M
US$ 1.520B
US$ 17.43
-0.01 -0.06
771,595
86.43M
US$ 1.510B
US$ 8.56
-0.08 -0.93
3.75M
172.17M
US$ 1.470B
C$ 5.05
-0.06 -1.17
1.42M
248.96M
C$ 1.260B
US$ 9.63
0.18 1.90
1.42M
115.03M
US$ 1.110B
US$ 9.41
-0.17 -1.77
2.93M
107.00M
US$ 1.010B
US$ 9.22
0.01 0.11
600,817
91.04M
US$ 839.390M
US$ 8.36
-0.09 -1.07
1.48M
89.70M
US$ 749.890M
US$ 8.50
-0.29 -3.30
874,426
77.11M
US$ 655.440M
US$ 7.39
0.16 2.21
433,806
78.15M
US$ 577.530M
US$ 2.44
-0.16 -6.15
3.31M
186.64M
US$ 455.400M
US$ 2.67
-0.09 -3.26
2.08M
168.92M
US$ 451.020M
US$ 3.07
-0.05 -1.60
43,428
139.82M
US$ 429.250M
US$ 2.78
0.01 0.36
870,756
138.95M
US$ 386.280M
US$ 2.88
0.11 3.97
2.72M
114.86M
US$ 330.800M
US$ 14.05
0.11 0.79
54,554
23.48M
US$ 329.890M
US$ 5.44
-0.17 -3.03
1.39M
58.52M
US$ 318.350M
US$ 6.59
-0.06 -0.90
967,240
45.20M
US$ 297.870M
US$ 4.60
0.07 1.55
662,425
60.85M
US$ 279.910M
C$ 1.57
-0.06 -3.68
337,574
165.88M
C$ 260.430M
US$ 3.68
0.00 0.00
29,138
66.44M
US$ 244.500M
US$ 5.84
-0.01 -0.17
193,253
37.47M
US$ 218.820M
US$ 8.74
0.00 0.00
227,612
18.42M
US$ 160.990M
US$ 5.00
1.01 25.31
2,275
27.08M
US$ 135.400M
C$ 0.11
0.00 0.00
0
100.02M
C$ 11.000M
US$ 0.77
-0.08 -9.65
331,843
153.83M
US$ 118.140M
US$ 2.35
0.00 0.00
0
49.43M
US$ 116.160M
US$ 0.65
-0.02 -3.58
564,829
158.72M
US$ 103.170M
US$ 3.08
-0.07 -2.22
32,249
32.20M
US$ 99.180M
US$ 0.70
0.0027 0.39
443,103
125.80M
US$ 87.930M
C$ 1.14
-0.03 -2.56
152,900
74.08M
C$ 84.450M
US$ 2.22
0.17 8.29
591,187
37.10M
US$ 82.360M
US$ 2.00
-0.06 -2.91
12,259
31.02M
US$ 62.040M
US$ 1.54
-0.05 -3.14
421,542
37.42M
US$ 57.630M
US$ 2.14
-0.06 -2.73
126,053
26.35M
US$ 56.390M
US$ 2.01
0.07 3.61
49,241
26.67M
US$ 53.610M
C$ 0.57
-0.01 -1.72
18,500
93.38M
C$ 53.230M
US$ 1.73
0.05 2.98
252,296
27.60M
US$ 47.750M
US$ 2.02
0.14 7.45
32,059
22.41M
US$ 45.270M
US$ 0.78
-0.02 -2.48
371,896
57.89M
US$ 45.040M
US$ 4.41
0.10 2.32
835,392
9.39M
US$ 41.410M
US$ 3.72
0.07 1.92
17,592
10.78M
US$ 40.100M
C$ 0.30
-0.005 -1.67
9,000
113.10M
C$ 33.360M
C$ 0.19
-0.005 -2.63
160,509
159.67M
C$ 29.540M
US$ 0.18
0.0029 1.63
439,972
162.86M
US$ 29.480M
US$ 0.07
0.0084 13.64
97,000
407.29M
US$ 28.510M
US$ 1.28
-0.06 -4.48
557,061
20.75M
US$ 26.560M
US$ 1.48
-0.06 -3.90
521,951
16.26M
US$ 24.060M
US$ 0.30
-0.01 -3.23
104,135
77.45M
US$ 23.240M
C$ 0.25
0.00 0.00
0
90.89M
C$ 22.720M
US$ 9.31
-0.10 -1.06
10,538
2.40M
US$ 22.340M
US$ 2.41
-0.02 -0.82
1,846
8.39M
US$ 20.220M
US$ 2.38
-0.10 -4.03
39,719
7.09M
US$ 16.870M
US$ 0.41
-0.01 -3.41
777,593
40.44M
US$ 16.700M
US$ 0.71
-0.03 -4.09
109,570
22.45M
US$ 16.010M
US$ 1.81
-0.09 -4.74
67,842
8.71M
US$ 15.770M
US$ 0.55
-0.03 -5.93
117,714
27.99M
US$ 15.390M
US$ 0.44
0.01 2.92
448,950
31.06M
US$ 13.670M
US$ 2.01
-1.10 -35.37
16,358
6.63M
US$ 13.310M
C$ 0.09
-0.005 -5.26
149,000
140.64M
C$ 12.660M
US$ 0.52
-0.23 -30.67
1.34M
23.12M
US$ 12.020M
C$ 0.03
-0.005 -16.67
50,000
451.63M
C$ 11.290M
US$ 0.47
-0.008 -1.67
2.35M
23.87M
US$ 11.270M
US$ 0.48
-0.0071 -1.46
104,582
23.26M
US$ 11.120M
US$ 1.56
-0.04 -2.50
1.01M
6.67M
US$ 10.410M
C$ 0.10
-0.02 -13.04
251,500
90.29M
C$ 9.030M
US$ 3.96
-0.31 -7.28
275,151
2.22M
US$ 8.790M
US$ 0.36
0.00 0.00
0
24.39M
US$ 8.780M
US$ 3.20
0.08 2.56
455,942
2.71M
US$ 8.670M

Latest News From Biotech and Pharma Companies Using Artificial Intelligence


Alpine ENT Expands Partnership with CareCloud, Implements FrontDesk Assist to Enhance Patient Experience

SOMERSET, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDO), a leading provider of healthcare technology and AI-powered revenue cycle management (RCM) solutions, today announced the expanded adoption of its services by Alpine Ear, Nose & Throat PC, a premier otolaryngology group based in Colorado. Following a successful RCM engagement, Alpine ENT has now implemented CareCloud FrontDesk Assist—a comprehensive front-office... Read more


Charles River Laboratories and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering’s in-house drug development unit WILMINGTON, Mass. & CAMBRIDGE, Mass. / Mar 25, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications... Read more


Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines

VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif., March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI Solutions, headquartered... Read more


Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds represent true drug discovery using Predictive's active machine learning platform PITTSBURGH, March 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has successfully developed predictive... Read more


Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business

Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the "LOI") to acquire all of the issued and outstanding shares (the "Transaction") of Monjin Interviews Private Limited ("Monjin"), a corporation formed under the laws of India. The Transaction is an arm's length transaction. About Monjin - https://www.monjin.c... Read more


Ventripoint Diagnostics Publishes Whitepaper on the Use of AI in Whole-Heart Analysis

Toronto, Ontario – TheNewswire - March 24, 2025 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce the release of a whitepaper comparing the performance of the VMS+™4.0 advanced Automated Radiological Image Processing Software/System to the previous basic model, VMS+ 3.0. This latest advancement of Ventripoint’s proprietary technology, VMS+ 4.0, which recently received U.S. FDA 510(k) clearance, delivers a... Read more


GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts

The latest Invenia ABUS is designed to deliver optimal outcomes with its innovative, patient-friendly, and efficient AI-driven technology Invenia ABUS Premium features new integrated Verisound AI and AI Assistant, which ensure faster and reproducible scanning and reading with extraordinary image quality The non-invasive ultrasound technology, equipped with a novel Reverse Curve transducer and separate acquisition and reading capabilities, is built to enhance patient... Read more


ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review

Adoption allows ICON to take full advantage of the Medidata “Data Experience,” leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK / Mar 20, 2025 / Business Wire / Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will... Read more


Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI

SUNNYVALE, Calif. and SECAUCUS, N.J., March 18, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a collaboration with Google Cloud to streamline Quest's data management, improve data analytics, and personalize the experiences Quest delivers to patients, providers and other customers. To do so, Quest Diagnostics will use Google Cloud's data analytics and generative AI (gen AI) technologies, including Google... Read more


Hyperfine and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation

Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. GUILFORD, Conn. / Mar 17, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration leverages NVIDIA AI expertise and... Read more


Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress. Partex will deploy its proprietary AI-based drug discovery and development technology platform, which delivers... Read more


Perimeter Medical Imaging AI Files FDA PMA Application for its Next-Generation B-Series OCT with ImgAssist AI 2.0

TORONTO and DALLAS, March 17, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced the submission of a Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the Company's next-generation Perimeter B-Series OCT system, which combines proprietary artificial intelligence ("AI") technology with optical coherence... Read more


Spectral AI Announces Successful Results from its Burn Validation Study of the DeepView System

DeepView® System outperforms burn physicians in identifying non-healing tissue Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView’s performance Spectral AI plans FDA submission by mid-2025, targeting De Novo Clearance and rapid commercialization to transform burn care DALLAS, March 17, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, that... Read more


GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

GeneDx's Multiscore tool to be showcased at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting GAITHERSBURG, Md. / Mar 13, 2025 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Multiscore, an advanced AI-powered decision support tool designed to revolutionize genetic analysis by improving diagnostic efficiency, streamlining workflows, and enhancing clinical insights.... Read more


MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

MeiraGTx to receive $200 million in upfront cash consideration MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson’s disease through to commercialization, as well as other potential pipeline products MeiraGTx will enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd to manufacture AAV-GAD and other locally... Read more


Next-Gen Cancer Treatment: Rakovina Therapeutics’ AI-Driven ATR Inhibitors Enter Preclinical Testing

VANCOUVER, British Columbia, March 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, announced today that the company has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in collaboration with Variational AI. This milestone marks a significant step forward in Rakovina’s mission... Read more


Tempus Announces Acquisition of Deep 6 AI

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO / Mar 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep... Read more


Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing

Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories With this collaboration, Ainos takes a major step in its mission to digitize scent - expanding its expertise from healthcare applications to industrial automation. AI Nose, originally developed for volatile organic compound (VOC) detection in medical diagnostics, is now expanding to smart factories. By unlocking insights from invisible chemical patterns in the air, AI Nose has... Read more


COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS’ NexGenAI Affiliates Network “NexGen” and NUBURU, Inc. “NUBURU” (NYSE: BURU), a leading innovator in high-power blue laser technology. This collaboration is a pivotal component of COEPTIS’ strategic position in technology... Read more


Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with... Read more


PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing of its previously announced acquisition of 100% of the business activity of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd, a public company registered under the laws of the State of Israel,... Read more


Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Strategic collaboration harnesses GATC’s proprietary Artificial Intelligence-powered, validated Multiomics Advanced Technology™ platform to rapidly optimize and derisk drug discovery and development, thereby accelerating and economizing the traditional drug development process. Lisata’s investigational product, certepetide, to be the subject of a comprehensive AI-analysis to determine optimum disease targets and development strategies. GATC to leverage Lisata’s... Read more


IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the development of a new AI-driven model designed to improve the diagnosis of Alzheimer's disease (AD) and other causes of dementia. With Alzheimer's accounting for approximately 60-80% of all dementia cases, alongside other conditions such as vascular disease, Lewy body disease,... Read more


Clover Health: Counterpart Health Partners with Google Cloud to Improve Clinical Data Access for Physicians

WILMINGTON, Del., March 03, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform, today announced it has partnered with Google Cloud to integrate Vertex AI Search into its flagship technology, Counterpart Assistant. This innovation gives providers on Counterpart Assistant a generative AI (gen AI) search experience across the breadth of a patient’s digital health record to provide contextualized insights,... Read more


IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets

SOUTH SAN FRANCISCO, Calif., March 3, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced a research collaboration with ATTMOS as part of its efforts to build a physics-based computational small molecule discovery platform that rapidly unlocks what are currently perceived as undruggable oncology targets. The collaboration will integrate IDEAYA's... Read more



Rakovina Therapeutics and Variational AI Strengthen Partnership

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, proudly reaffirms its strategic partnership with Variational AI. This announcement comes on the heels of Variational AI’s impressive $5.5 million oversubscribed financing round, led by Nimbus Synergies with participation from Flying Fish Ventures, Merck Global... Read more


ImmunoPrecise Antibodies and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

AUSTIN, Texas / Feb 26, 2025 / Business Wire / ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO’s advanced... Read more


HEALWELL AI's VeroSource Unveils Digital Twin Technology to Bring Real-Time Intelligence to Healthcare Management

VeroSource to support cutting edge Digital Twin technology on its VS Data-as-a-Service Platform, delivering real-time insights and advanced data visualization to optimize healthcare operations. A Digital Twin is a virtual model of a healthcare system or facility that provides real-time insights for better decision-making. By simulating operations without disruption, this technology allows healthcare managers to optimize efficiency, reduce costs, and enhance patient care. Key... Read more


RadNet: DeepHealth Introduces New AI-Powered Radiology Informatics and Population Screening Solutions at #ECR2025

At ECR 2025, DeepHealth will introduce new AI-powered radiology informatics and cancer screening solutions enabled by DeepHealth OS, its pioneering cloud-native operating system, to address clinical and operational challenges. DeepHealth aims to bring to European customers its Diagnostic Suite™ to redefine the traditional Picture Archiving and Communication System (PACS) with a unified workspace tailored for modern radiology, and SmartMammo™, an AI-powered end-to-end... Read more


Netramark And The Ontario Brain Institute Partner To Advance AI-Powered Neuroanalytics For Major Depression Research

TORONTO, Feb. 25, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, announces its funded collaboration with the Ontario Brain Institute (OBI) to enhance the analysis of brain imaging and multi-modal data from Major Depressive Disorder (MDD) clinical research to achieve treatment separation in future clinical trials. The collaboration,... Read more


RadNet’s Wholly-Owned Subsidiary, DeepHealth, and ConcertAI’s TeraRecon Announce Strategic Collaboration Around Integrated AI and Advanced Visualization

DeepHealth’s cloud-native Diagnostic Suite™ will integrate TeraRecon’s SaaS-based advanced visualization capabilities, creating a unified AI-powered diagnostic workspace that enhances workflows and expands access to advanced diagnostic tools across diverse healthcare settings. The collaboration will also integrate DeepHealth’s clinical AI solutions into TeraRecon’s AI ecosystem, augmenting its capabilities and expanding its impact in diagnostic imaging. Both... Read more


Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions, announced that they have entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology... Read more



HEALWELL AI's Khure Health Provides Update Highlighting Significant Acceleration in User and Life Sciences Partner Adoption of Disease Detection AI Powered Co-Pilots and Strong Physician NPS Scores

In Q4-2024, HEALWELL's subsidiary, Khure Health ("Khure") helped physicians identify over 43,000 high-risk patients with its AI-Powered Physician Co-Pilots, across 8 clinical specialities harnessing 132 disease specific algorithms. This figure reflected a quarter over quarter sequential growth of 22% as compared to Q3-2024 and year-over-year growth of 500% as compared to Q4-2023. HEALWELL has executed 4 new Master Services Agreements ("MSA") with new pharmaceutical partners... Read more


COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu, a prominent developer within the open-source Verus Project, which has recently achieved a market capitalization exceeding $500 million. This collaboration aims to integrate... Read more


Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte receives exclusive rights to develop and commercialize collaboration products WILMINGTON, Del. & BURLINGAME, Calif. / Feb 20, 2025 / Business Wire / Incyte (Nasdaq:INCY) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration... Read more


Conduit Pharmaceuticals Progresses Phase II of its AI Initiative with Sarborg

Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development Sarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial milestones in Phase II... Read more



PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the... Read more


Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types Creates significant business development opportunities with meaningful long-term commercial potential with large pharmaceutical companies PITTSBURGH, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today provided an update highlighting new successes... Read more


Kovo+ Announces Letter of Intent to Acquire Exclusive Rights to AI Vector and Veebas

Vancouver, British Columbia--(Newsfile Corp. - February 13, 2025) - Kovo+ Holdings Inc. (formerly Kovo HealthTech Corporation) (TSXV: KOVO) ("Kovo" or the "Company") is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with Avonlea Ventures #2 Inc. ("AVI"), whereby the Company intends to acquire (the "Proposed Transaction") certain contractual assets of AVI, including the exclusive right to acquire, among other things: (i) all of the... Read more


CareSpan Health Enters Into Definitive Agreement With Medtech AI And Concurrent Financing

VANCOUVER, BC, Feb. 13, 2025 /CNW/ - CareSpan Health, Inc. (TSXV: CSPN) (the "Company" or "CareSpan"), announces that it has entered into a binding definitive agreement among Medtech AI Inc. ("Medtech"), a company incorporated under the laws of Ontario, and 1001132953 Ontario Inc., a company existing under the laws of Ontario, (the "SubCo") effective as of February 11, 2025 (the "Definitive Agreement"), whereby CareSpan will acquire all the issued and outstanding common... Read more


HEALWELL AI's Pentavere Publishes Study in the Journal of Liquid Biopsy; Validating DARWEN(TM) AI as a Leading Artificial Intelligence Clinical Decision Support Tool in Oncology

The use of the DARWEN™ AI platform achieved time savings representing a 100-fold improvement as compared to traditional manual processes(1), demonstrating the opportunity to advance care and improve patient outcomes by leveraging cutting edge AI technology in clinical care. This study was conducted in collaboration with Princess Margaret Cancer Centre and is one of the world's first peer-reviewed studies to use an artificial intelligence platform to demonstrate... Read more


Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of two new patent applications, covering groundbreaking developments in the treatment... Read more


Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”),... Read more


Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function REDWOOD CITY, Calif. , Feb. 6, 2025 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology. CZI is embarking on this landmark initiative... Read more


Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, announces continued advancement of its AI-driven drug discovery program. Over the next four months, additional small-molecule drug candidates, designed in collaboration with Pharma Inventor Inc., will be synthesized and delivered for further evaluation. The expanded... Read more


Clover Health: Counterpart Health Signs Multi-Year Agreement with Southern Illinois Healthcare

WILMINGTON, Del., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced a strategic, multi-year agreement with Southern Illinois Healthcare (SIH), a regional leader in healthcare delivery and the largest health system in Southern Illinois. Counterpart is a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”). This partnership will enable SIH’s care teams... Read more


Inspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor

Inspira Technologies develops its innovative AI-powered HYLA technology with advanced blood testing capability, enabling continuous monitoring of tissue oxygenation and early hypoxia detection; Company expects to release preliminary clinical results for the sensor in the near future RA'ANANA, Israel, Feb. 5, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology,... Read more